Submission Tilte
Current Paradigms in the Treatment of Hematologic Malignancies in HIV-Infected Patients. The Role of New Platforms, including Bispecific Therapy and C ART in Patients with HIV and Lymphoma
Submission Abstract:
This thematic issue explores the evolving interface between lymphoma care and HIV medicine in the era of immune-engaging therapies. We will review contemporary epidemiology and biologic features of HIV-associated lymphomas, the impact of antiretroviral therapy on treatment selection, and practical approaches to staging, supportive care, and infection prophylaxis. A central focus is the safe, effective use of bispecific antibodies and CAR T-cell therapy in people with HIV, including eligibility criteria, management of drug–drug interactions, viral load/CD4 considerations, and strategies to mitigate cytokine release syndrome, neurotoxicity, cytopenias, and opportunistic infections. Contributors will address real-world data, ongoing trials, and regulatory/access barriers, with attention to disparities and global applicability. Articles will highlight multidisciplinary models that integrate oncology, infectious diseases, pharmacy, and cellular therapy programs, and will propose evidence-informed algorithms for sequencing bispecifics, CAR-T, transplantation, and novel agents across frontline and relapsed/refractory settings. We also discuss biomarkers, resistance mechanisms, and directions for curative research.